Specific targeted therapy of chronic myelogenous leukemia with imatinib

Michael W N Deininger, Brian Druker

Research output: Contribution to journalArticle

245 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib asa specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.

Original languageEnglish (US)
Pages (from-to)401-423
Number of pages23
JournalPharmacological Reviews
Volume55
Issue number3
DOIs
StatePublished - Sep 2003

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Chromosomes, Human, Pair 22
Chromosomes, Human, Pair 9
Myeloid Cells
Drug Combinations
Cytogenetics
Protein-Tyrosine Kinases
Signal Transduction
Adenosine Triphosphate
Imatinib Mesylate
Genes
Proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Specific targeted therapy of chronic myelogenous leukemia with imatinib. / Deininger, Michael W N; Druker, Brian.

In: Pharmacological Reviews, Vol. 55, No. 3, 09.2003, p. 401-423.

Research output: Contribution to journalArticle

@article{c2c0846cdad34d2b906377649250bf9e,
title = "Specific targeted therapy of chronic myelogenous leukemia with imatinib",
abstract = "Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib asa specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.",
author = "Deininger, {Michael W N} and Brian Druker",
year = "2003",
month = "9",
doi = "10.1124/pr.55.3.4",
language = "English (US)",
volume = "55",
pages = "401--423",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Specific targeted therapy of chronic myelogenous leukemia with imatinib

AU - Deininger, Michael W N

AU - Druker, Brian

PY - 2003/9

Y1 - 2003/9

N2 - Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib asa specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.

AB - Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9. The chimerical Bcr-Abl protein expressed by CML cells has constitutive tyrosine kinase activity, which is essential for the pathogenesis of the disease. Imatinib, an ATP-competitive selective inhibitor of Bcr-Abl, has unprecedented efficacy for the treatment of CML. Most patients with early stage disease achieve durable complete hematological and complete cytogenetic remissions, with minimal toxicity. In contrast, responses are less stable in patients with advanced CML. This review highlights the pathogenesis of CML, its clinical features, and the development of imatinib asa specific molecularly targeted therapy. Aspects of disease monitoring and side effects are covered as well as resistance to imatinib and strategies to overcome resistance, such as alternative signal transduction inhibitors and drug combinations. Perspectives for further development are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0041466445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041466445&partnerID=8YFLogxK

U2 - 10.1124/pr.55.3.4

DO - 10.1124/pr.55.3.4

M3 - Article

VL - 55

SP - 401

EP - 423

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 3

ER -